Delivering bioactive cyclic peptides that target Hsp90 as prodrugs

Autor: Yuantao Huo, Laura K. Buckton, Jack L. Bennett, Eloise C. Smith, Frances L. Byrne, Kyle L. Hoehn, Marwa N. Rahimi, Shelli R. McAlpine

Publikováno v: Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 34, Iss 1, Pp 728-739 (2019)

The most challenging issue facing peptide drug development is producing a molecule with optimal physical properties while maintaining target binding affinity. Masking peptides with protecting groups that can be removed inside the cell, produces a cel

Externí odkaz: https://doaj.org/article/6788bb62f2ca40478336fde2257a8a2c

Human IgG1 antibodies suppress angiogenesis in a target-independent manner

Autor: Tetsuhiro Yasuma, Hiroko Terasaki, Mike Clark, Valeria Cicatiello, Laura Tudisco, Yuichiro Ogura, Wallace Y. Langdon, Judit Z. Baffi, Miho Nozaki, Pierre Bruhns, Younghee Kim, Parthasarathy Arpitha, Sasha Bogdanovich, Nagaraj Kerur, Takeshi Mizutani, Yoshio Hirano, Bradley D. Gelfand, Benjamin J. Fowler, Balamurali K. Ambati, Ivana Apicella, Kathryn L. Armour, Shengjian Li, Sandro De Falco, Ryo Ijima, Hiroki Kaneko, Ana Bastos-Carvalho, Valeria Tarallo, Jeanette H. W. Leusen, Charles B. Wright, Jayakrishna Ambati, J. Sjef Verbeek, Arturo Brunetti, Reo Yasuma, Annamaria Sandomenico, Adelaide Greco, Menotti Ruvo

Publikováno v: Signal Transduction and Targeted Therapy, 1. NATURE PUBLISHING GROUP
Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy, Nature.com, 2016, 1, pp.15001. ⟨10.1038/sigtrans.2015.1⟩
Signal Transduction and Targeted Therapy, 2016, 1, pp.15001. ⟨10.1038/sigtrans.2015.1⟩
Signal Transduction and Targeted Therapy ( 1 (2016): 15001. doi:10.1038/sigtrans.2015.1
info:cnr-pdr/source/autori:Bogdanovich, Sasha; Kim, Younghee; Mizutani, Takeshi; Yasuma, Reo; Tudisco, Laura; Cicatiello, Valeria; Bastos-Carvalho, Ana; Kerur, Nagaraj; Hirano, Yoshio; Baffi, Judit Z; Tarallo, Valeria; Li, Shengjian; Yasuma, Tetsuhiro; Arpitha, Parthasarathy; Fowler, Benjamin J; Wright, Charles B; Apicella, Ivana; Greco, Adelaide; Brunetti, Arturo; Ruvo, Menotti; Sandomenico, Annamaria; Nozaki, Miho; Ijima, Ryo; Kaneko, Hiroki; Ogura, Yuichiro; Terasaki, Hiroko; Ambati, Balamurali K; Leusen, Jeanette Hw; Langdon, Wallace Y; Clark, Michael R; Armour, Kathryn L; Bruhns, Pierre; Verbeek, J Sjef; Gelfand, Bradley D; De Falco, Sandro; Ambati, Jayakrishna/titolo:Human IgG1 antibodies suppress angiogenesis in a target-independent manner./doi:10.1038%2Fsigtrans.2015.1/rivista:Signal Transduction and Targeted Therapy (/anno:2016/pagina_da:15001/pagina_a:/intervallo_pagine:15001/volume:1
Signal transduction and targeted therapy, 1. Springer Nature

Aberrant angiogenesis is implicated in diseases affecting nearly 10% of the world’s population. The most widely used anti-angiogenic drug is bevacizumab, a humanized IgG1 monoclonal antibody that targets human VEGFA. Although bevacizumab does not r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a748982605123f93b3715b7cbf03313
http://hdl.handle.net/11588/636288